When patents for Reference Listed Drugs (RLDs) expire, it opens the door for generic manufacturers to offer more affordable alternatives to brand-name drugs. However, successful entry into the market requires careful preparation ahead of the patent expiration. To demonstrate that a generic drug is equivalent to its branded counterpart, companies conduct thorough clinical research. This […]

Read More →

For anyone seeking generic drug approval in the USA, a Bioavailability and Bioequivalence (BA/BE) study is often a critical step. These studies show the FDA that your product works just like the approved brand-name version, meeting strict guidelines for safety and effectiveness. Choosing the right global location for your trial, managing costs, and ensuring the […]

Read More →